Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Hyperfine portable MR imaging system wins award

Hyperfine has won the American College of Emergency Physicians 2020 incubatED Medical Device Innovation Challenge, recognizing the company’s Swoop™ Portable MR Imaging System. “Portable MR...

| By Kelley Gipson

BI names Yew Looi Liew to U.S. Human Pharma post

Boehringer Ingelheim has appointed Yew Looi Liew (YL) President of U.S. Human Pharma at its U.S. headquarters. In his new role, Mr. Liew is responsible for...

| By Kelley Gipson

Vanessa reports European advance for Shylicine™

Vanessa Research has been granted a positive orphan drug opinion by the European Medicines Agency for the drug Shylicine™ (patent pending). The drug is used to treat...

| By Kelley Gipson

Taconic offers mouse model for COVID-19 research

Taconic Biosciences reports the immediate availability of humanized ACE2 mouse model for COVID-19 research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells....

| By Kelley Gipson

FDA approves BioXcel application re delirium

The FDA has greenlighted the application from BioXcel Therapeutics to begin a clinical trial on its agitation drug for patients with delirium. This would be the...

| By Kelley Gipson

Stamford biotechs Cara and SpringWorks report deals

Biotech firms Cara Therapeutics and SpringWorks Therapeutics have announced licensing and acquisition deals that could be worth several hundred million dollars. Cara signed a deal with Vifor Pharma for the...

| By Kelley Gipson

CaroGen reports progress re ovarian cancer

CaroGen reports that significant progress has been made in collaboration with Wayne State University in developing CARG-2020 for potential treatment of patients with ovarian cancer and other...

| By Kelley Gipson

Rocky Hill’s Lumeda names first CEO

Rocky Hill-based Lumeda, a startup that is developing an optical device to target cancer-killing laser light during lung cancer surgery, has named its first CEO. Alexander...

| By Kelley Gipson

CRISPR biotech targets cancer, autoimmune disease

A new biotech that is using CRISPR gene-editing technology to discover drugs for cancer and autoimmune diseases is opening a lab in Branford after raising...

| By Kelley Gipson

ReNetX wins grant to advance spinal cord treatment

ReNetX Bio has been awarded a $3 million SBIR Phase II grant from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke. ReNetX...